The vaccine candidate is pre-qualified by the World Health Organization. Credit: Arek Socha from Pixabay.

China-based Sinopharm has commenced a Phase III clinical trial of its Covid-19 vaccine candidate at the Bahrain International Exhibition and Convention Centre (BIECC).

The trial received approval from the National Health Regulatory Authority (NHRA).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

During the study in Bahrain, Sinopharm’s inactivated vaccine candidate will be assessed for its effectiveness in antibody generation and the acquired protection against the virus.

The vaccine candidate is pre-qualified by the World Health Organization and participants can register via the National Volunteer Platform.

The Phase III trial involves up to 6,000 volunteers aged more than 18 years, according to the Bahrain Ministry of Health.

In a statement, the Ministry of Health said: “The move is part of the steps taken within the on-going efforts to contain the novel coronavirus pandemic and limit its spread through stepping up all precautionary and preventive measures to protect the health and safety of everyone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The Health Ministry highlighted its keenness to facilitate the procedures and mechanisms that enable volunteering citizens and residents to join the third phase of the clinical trial of the potential vaccine, enlisted by the World Health Organization.”

Last month, Sinopharm initiated the Phase III trial to assess its Covid-19 vaccine candidate in Abu Dhabi, UAE.

The trial in UAE is being conducted by Sinopharm’s China National Biotec Group (CNBG) in alliance with the Abu Dhabi Government and artificial intelligence firm G42 Healthcare.

Health practitioners from Abu Dhabi Health Services (SEHA) agreed to manage the study. Participation of up to15,000 volunteers has been authorised.

Sinopharm has also obtained approvals to test its potential Covid-19 vaccine in Argentina, Peru and Morocco, reported Reuters.

The vaccine candidate is said to have demonstrated encouraging profile in the first two trial phases conducted by the company in China.